Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4ZIDH)

Drug Name

Xentuzumab Drug Info

Indication

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Insulin-like growth factor-I (IGF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MEDI-573	DMNL8MO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
BI-836845	DM4T916	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
------------------------------------------------------------------------------------

Drug(s) Targeting Insulin-like growth factor-II (IGF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dusigitumab	DM1ZJYS	Breast cancer	2C60-2C65	Phase 2	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin-like growth factor-I (IGF1)	TTT6LOU	IGF1_HUMAN	Not Available	[2]
Insulin-like growth factor-II (IGF2)	TTE8WGO	IGF2_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03659136) The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4	Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.Mol Cancer Ther.2014 Feb;13(2):399-409.